ReviewBMC endocrine disorders2022
Ovarian steroid cell tumors, not otherwise specified: analysis of nine cases with a literature review.
Review in BMC endocrine disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Silent Ovary with a Loud Hormonal Signal: A Case Report and Literature Review of an Androgen-Secreting Stromal Luteoma.Journal of clinical medicine · 2026Article
- The oncology and fertility outcomes in patients with ovarian steroid cell tumors: a single center experience.Journal of ovarian research · 2026Article
- Evaluation and management of worsening virilization in a postmenopausal woman diagnosed with PCOS.Journal of the Endocrine Society · 2026Article
- Malignant transformation of a testosterone-secreting ovarian steroid cell tumor: a case report.Gynecologic oncology reports · 2026Article
- Ovarian steroid cell tumor in a teenager masquerading as polycystic ovary syndrome: a case report and literature review.Journal of ovarian research · 2025Review
- Ovarian steroid cell tumors, not otherwise specified: three case reports and literature review.Frontiers in oncology · 2024Article
- Ovarian steroid cell tumors: what do we know so far?Frontiers in oncology · 2024Review
- Relevance of Molecular Pathology for the Diagnosis of Sex Cord-Stromal Tumors of the Ovary: A Narrative Review.Cancers · 2023Review
- An unusual presentation of sex cord-stromal tumors.Internal and emergency medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOvarian steroid cell tumors (SCTs), not otherwise specified (NOS), are rare, with few large studies. The purpose of this study was to analyze the clinical features, prognosis, and treatment choices for these patients of different age groups.
methodsThis was a retrospective study. We identified nine cases of ovarian steroid cell tumor, not otherwise specified, confirmed by post-operative histopathological examination, and analyzed clinical features, surgical procedures, and follow up outcomes. We also reviewed cases reports of ovarian steroid cell tumors, not otherwise specified.
resultsA total of nine cases were included. The age range was 9-68 years (mean, 41.89 ± 19.72 years). Clinical features included virilization, amenorrhea, abdominal pain, vaginal bleeding, isosexual precocious puberty, Cushing's syndrome, and abnormal weight gain with elevated testosterone levels. The follow up interval ranged 5-53 months and no recurrence was observed.
conclusionOvarian steroid cell tumors covered all age groups, with manifestations of androgen excess. Younger patients appeared to have a more favorable prognosis, which provided more opportunities for these patients to pursue treatment options that will preserve reproductive function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.